11.24.17
Pertinax Pharma appointed Nigel Brooksby as chairman of the company. His chief responsibilities will be to assist in corporate, strategic and business development moves into its commercialization phase following the launch last month of Pertinax. This unique technology which enables controlled and sustained release of the antimicrobial, chlorhexidine (CHX) has wide ranging potential applications, spanning the wound care, medical device, dental and veterinary markets.
Brooksby is highly regarded as an experienced businessman and entrepreneur in the life sciences arena. Over the last seven years, he has been involved as chairman, director and strategic adviser in raising significant investment. In his role as chairman of the UK Life Sciences Strategy Board, he secured a £32 million bid from the UK Government for the continued expansion and development of skills for the life sciences sector. In 2015, he was instrumental in gaining a listing for a clinical stage biopharma company on NASDAQ, in which he continues to be a key investor and director. He has been a long-standing investor and strategic adviser in a novel biotechnology company that achieved an AIM listing earlier this year. Under the auspices of his company, Steel-Bars Ltd, through his extensive network of contacts in global pharma companies at CEO level, Brooksby has undertaken many projects in partnering biotech companies with big pharma. He is also a non-executive director at Porton Biopharma, a director of Stabilitech Pharma, and a non-executive director at Chronos Therapeutics. Brooksby is also chairman of Clinical Insights Ltd and Neurocentrx Pharma.
Brooksby is a past president of the Association of the British Pharmaceutical Industry (ABPI) and received the honour of lifetime member in recognition of his services to the life sciences. He holds several academic, charity and life sciences chairmanships and senior board positions including chairman of the Pharmaceutical Directors Club (PDC).
"Pertinax has enormous market potential in multiple fields," said Brooksby. "We are already in talks with several manufacturers and over the course of the next 12 months, we confidently expect to have applications of Pertinax in development for use in wound care, veterinary and dental products.”
“His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand," said Michele Barbour, founder and CSO of Pertinax Pharma.
Brooksby is highly regarded as an experienced businessman and entrepreneur in the life sciences arena. Over the last seven years, he has been involved as chairman, director and strategic adviser in raising significant investment. In his role as chairman of the UK Life Sciences Strategy Board, he secured a £32 million bid from the UK Government for the continued expansion and development of skills for the life sciences sector. In 2015, he was instrumental in gaining a listing for a clinical stage biopharma company on NASDAQ, in which he continues to be a key investor and director. He has been a long-standing investor and strategic adviser in a novel biotechnology company that achieved an AIM listing earlier this year. Under the auspices of his company, Steel-Bars Ltd, through his extensive network of contacts in global pharma companies at CEO level, Brooksby has undertaken many projects in partnering biotech companies with big pharma. He is also a non-executive director at Porton Biopharma, a director of Stabilitech Pharma, and a non-executive director at Chronos Therapeutics. Brooksby is also chairman of Clinical Insights Ltd and Neurocentrx Pharma.
Brooksby is a past president of the Association of the British Pharmaceutical Industry (ABPI) and received the honour of lifetime member in recognition of his services to the life sciences. He holds several academic, charity and life sciences chairmanships and senior board positions including chairman of the Pharmaceutical Directors Club (PDC).
"Pertinax has enormous market potential in multiple fields," said Brooksby. "We are already in talks with several manufacturers and over the course of the next 12 months, we confidently expect to have applications of Pertinax in development for use in wound care, veterinary and dental products.”
“His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand," said Michele Barbour, founder and CSO of Pertinax Pharma.
